14 results
DEFA14A
CVM
Cel-Sci Corp.
7 Mar 24
Additional proxy soliciting materials
11:33am
% in the control at 5 years
28.6% absolute 5-year overall survival benefit versus control; statistically significant p = 0.0015 and hazard ratio = 0.35
Tumor
424B5
CVM
Cel-Sci Corp.
9 Feb 24
Prospectus supplement for primary offering
8:44am
control (p=0.0015);
0.349 hazard ratio vs control (95% CIs [0.18, 0.66], Wald p=0.0012);35% rate of pre-surgery reductions and/or downstages (p<0.01 … to the potential positive effects of Multikine.
Another measure of survival benefit is called the “hazard ratio,” which compares the chances of dying
S-8
EX-99
CVM
Cel-Sci Corp.
22 Dec 23
Registration of securities for employees
4:01pm
benefit versus control (p=0.0015);
0.349 hazard ratio vs control (95% CIs [0.18, 0.66], Wald p=0.0012);35% rate of pre-surgery reductions … to the potential positive effects of Multikine.
Another measure of survival benefit is called the “hazard ratio,” which compares the chances of dying
424B5
0aagtlse34267
16 Nov 23
Prospectus supplement for primary offering
8:39am
8-K
EX-99.1
icu6ymw uqtf
30 Oct 23
Entry into a Material Definitive Agreement
5:01pm
8-K
EX-99
h2amal5gn98k
24 Oct 23
Other Events
10:18am
8-K
EX-99
u15bp 1ti3
12 Jul 23
Other Events
9:01am
8-K
EX-99.1
n7vvgdg8
22 Aug 22
Cel-sci Corporation Announces Phase 3 Multikine® Head and Neck Cancer Results Posted on Clinicaltrials.Gov
9:00am
8-K
EX-99
g9feo0mp 2iif
7 Jul 21
Other Events
3:24pm
- Prev
- 1
- Next